Oxygen therapy remains a cornerstone in managing respiratory distress in preterm infants, a population whose underdeveloped lungs cannot efficiently exchange gases. However, hyperoxia — the condition of excess oxygen in tissues and organs — has long been recognized as a contributor to oxidative stress and inflammation, pivotal factors in lung injury. The review rigorously synthesizes current molecular insights, revealing how hyperoxia induces endothelial dysfunction in the delicate pulmonary vasculature, leading to aberrant vascular remodeling and impaired angiogenesis. These vascular perturbations not only exacerbate alveolar simplification but also set the stage for compromised pulmonary hypertension, a common secondary complication in BPD patients.

The pathogenic mechanisms delineated in this review underscore the multifactorial nature of hyperoxia-induced injury. Reactive oxygen species (ROS) generation emerges as a central driver, instigating a cascade of cellular damage within endothelial cells and alveolar epithelium. The oxidative insult disrupts critical signaling pathways, including those mediated by vascular endothelial growth factor (VEGF) and nitric oxide (NO), both integral to maintaining vascular integrity and promoting angiogenesis. Crucially, the review details how hyperoxia suppresses VEGF expression, hindering normal capillary formation and leading to an environment prone to fibrosis and tissue remodeling rather than repair.

Beyond these molecular cascades, the review highlights the role of inflammatory mediators activated by hyperoxic injury. Pro-inflammatory cytokines and chemokines, attracted to the site of vascular damage, perpetuate a vicious cycle of inflammation and tissue destruction. This inflammatory milieu, when sustained chronically, further compromises pulmonary vascular architecture and function, accelerating BPD progression. The synergy between oxidative stress and inflammation thus forms a pathological nexus that magnifies pulmonary complications beyond initial oxygen toxicity.

Impressively, the review doesn’t stop at pathophysiological characterization. It offers a panoramic view of emerging therapeutic interventions aimed at mitigating hyperoxia-induced vascular injury. One promising approach centers on antioxidant therapies designed to neutralize excessive ROS and restore redox balance. Several preclinical studies referenced suggest that supplementation with agents such as N-acetylcysteine and superoxide dismutase mimetics shows potential in preserving endothelial function and attenuating lung damage. These antioxidants may intervene early in the injury cascade and modulate disease trajectory when applied judiciously in clinical settings.

Moreover, the authors explore strategies targeting the restoration of impaired angiogenic signaling. Experimental therapies designed to boost VEGF activity or enhance nitric oxide bioavailability are gaining traction. Pharmacologic agents that can upregulate endogenous protective pathways, including the activation of hypoxia-inducible factors (HIFs), show encouraging results in animal models by promoting healthy vascular growth and mitigating fibrosis. These findings suggest a paradigm shift where therapies might not only prevent injury but actively facilitate lung repair and regeneration.

Gene therapy and stem cell-based approaches also feature prominently in this comprehensive review. Mesenchymal stem cells (MSCs), renowned for their immunomodulatory and reparative properties, have demonstrated the capacity to ameliorate hyperoxia-induced damage in experimental BPD models. The authors carefully analyze the current landscape of clinical trials involving MSCs, discussing varying degrees of success and the challenges inherent in translating cell-based therapies into routine neonatal care. Nevertheless, these cutting-edge interventions hold transformative potential by fundamentally altering the lung microenvironment and promoting structural normalization.

The review further delves into the challenges of clinical translation, emphasizing the delicate balance required in oxygen titration protocols to minimize harm while fulfilling therapeutic needs. The need for individualized oxygen delivery strategies tailored to the infant’s developmental stage and lung maturity is underscored, advocating a precision medicine approach. Additionally, the authors call attention to the dearth of reliable biomarkers that could guide risk stratification and therapeutic monitoring — a gap that, if addressed, could revolutionize the management of BPD in the future.

In illuminating the mechanisms through which hyperoxia leads to pulmonary vascular injury, this review also places BPD within the broader context of chronic lung diseases. Similar oxidative and inflammatory processes implicated in adult pulmonary hypertension and chronic obstructive pulmonary disease (COPD) reveal potential for cross-disciplinary insights and shared therapeutic targets. Such perspectives broaden the horizon of neonatal lung research and foster collaborative innovation across disciplines.

The authors conclude with a prescient call for integrated, multidisciplinary research that bridges basic science, translational studies, and clinical trials. They argue convincingly that unraveling the complex signaling networks impacted by hyperoxia and validating targeted interventions require concerted efforts across molecular biology, pharmacology, and neonatology. This holistic approach promises to uncover not only new treatments but also preventions that could ultimately reduce the global burden of BPD and improve long-term respiratory outcomes for survivors of preterm birth.

Notably, this review also highlights the importance of recognizing the heterogeneity within BPD phenotypes, acknowledging that not all infants respond identically to oxygen exposure or interventions. Future research must dissect these phenotypic differences to ensure therapeutic strategies are appropriately personalized. This nuanced understanding will help circumvent one-size-fits-all approaches that have historically limited progress in this area.

In sum, Cai and colleagues have crafted a comprehensive and forward-looking synthesis that redefines how we perceive hyperoxia’s role in neonatal lung injury. By integrating mechanistic insights with emerging therapeutics, their work delineates a roadmap toward mitigating one of the most pervasive complications in neonatology. While challenges remain, this review energizes the scientific community with optimism that targeted strategies can dash the long-standing paradox of oxygen therapy, ultimately sparing vulnerable infants from the devastating sequelae of bronchopulmonary dysplasia.

This landmark article thus sets a new benchmark in understanding and addressing the pulmonary vascular injury that underpins BPD. It underscores the urgency and potential of harnessing molecular science and innovative treatments to rewrite the prognosis of preterm infants who rely on oxygen for survival but face consequential risks. As the neonatal field marches forward, such integrative and translational insights are crucial to transform hope into healing.

Subject of Research: Bronchopulmonary dysplasia (BPD) and hyperoxia-induced pulmonary vascular injury in preterm infants.

Article Title: Hyperoxia and pulmonary vascular injury in bronchopulmonary dysplasia: pathogenic mechanisms and emerging therapies—a systematic review.

Article References:
Cai, J., Yang, Y., Zhang, H. et al. Hyperoxia and pulmonary vascular injury in bronchopulmonary dysplasia: pathogenic mechanisms and emerging therapies—a systematic review. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05150-w

Image Credits: AI Generated

DOI: 08 June 2026

Bronchopulmonary dysplasia continues to pose a considerable challenge in neonatal intensive care units (NICUs) worldwide. It is characterized by disrupted lung development, inflammation, and scarring, which can lead to long-term respiratory complications, impaired growth, and neurodevelopmental delays. BPD is notably prevalent among extremely premature infants who require respiratory support during their critical earliest days of life. Traditional approaches using invasive mechanical ventilation, while lifesaving, often exacerbate lung injury through barotrauma and volutrauma. Consequently, clinicians have explored NIV to better preserve lung architecture and function.

Despite growing enthusiasm for NIV, conflicting evidence has emerged regarding its efficacy in curbing BPD rates. The study by Goffinon and colleagues provides a rigorous, propensity score-matched analysis comparing outcomes among preterm infants receiving early non-invasive ventilation versus those supported by conventional invasive methods. This methodologically robust approach attempts to control for the multiple confounding variables common in observational neonatal research — such as gestational age, birth weight, and severity of illness — thus offering a clearer picture of NIV’s true impact on BPD incidence.

The findings reveal a paradoxical trend: while the adoption of NIV has increased markedly over recent years, there has been a concomitant rise in BPD rates rather than the expected decline. This data challenges the conventional wisdom that non-invasive techniques inherently reduce lung injury and suggests that the clinical milieu surrounding these interventions is far more complex than previously appreciated. Several hypotheses may explain this counterintuitive outcome, including the possibility that NIV is being applied to increasingly vulnerable populations or that subtle ventilator-induced lung injuries persist even without intubation.

The study’s granular analysis also highlights the heterogeneity of BPD as a disease entity. Differences in phenotypic presentations, underlying pathophysiological mechanisms, and the timing of respiratory support initiation all influence outcomes. Furthermore, the variability in NIV strategies — such as continuous positive airway pressure (CPAP), nasal intermittent positive pressure ventilation (NIPPV), or high-flow nasal cannula (HFNC) — complicates direct comparisons and calls for tailored approaches rather than one-size-fits-all protocols.

A critical implication of these results is the need for comprehensive longitudinal monitoring, not only focused on immediate respiratory outcomes but also on the broader developmental trajectory of infants with or at risk of BPD. The interplay between oxygenation targets, nutritional status, infection control, and respiratory support parameters necessitates a multifaceted, multidisciplinary approach that goes beyond initial ventilation modality selection. Neonatologists must balance the benefits of less invasive ventilation techniques against the potential for delayed recognition of lung injury or inadequate respiratory support.

Moreover, the study underscores the importance of ongoing clinical trials and translational research to dissect the molecular and cellular mechanisms underpinning BPD in the context of evolving respiratory strategies. Emerging technologies such as lung ultrasound, biomarkers of inflammation, and advanced pulmonary function testing may offer valuable tools for early detection and individualized management of lung injury in this vulnerable population. These innovations promise to refine NIV protocols, optimize ventilatory parameters, and ultimately improve pulmonary outcomes.

Beyond the immediate neonatal period, the findings raise concerns about the long-term respiratory health of infants exposed to early NIV. The propensity score matching and data analysis employed in this study provide a template for future investigations into neurodevelopmental outcomes, pulmonary morbidity, and quality of life measures that follow preterm infants into childhood and beyond. This holistic view is essential in guiding parental counseling and resource allocation for high-risk populations.

The investigators also emphasize the need for standardized definitions and diagnostic criteria for BPD in the era of advanced respiratory care. Heterogeneity in clinical practice and outcome reporting complicates the interpretation of epidemiological trends and the translation of research findings into practice guidelines. Establishing consensus through international collaborations could harmonize care delivery and facilitate meta-analyses that better inform evidence-based interventions.

From a clinical standpoint, the rising incidence of BPD in the face of increased NIV utilization should prompt neonatologists to critically reassess the timing, indications, and delivery modalities of non-invasive respiratory support. Protocols must incorporate vigilant monitoring for signs of respiratory deterioration and readiness for escalation to invasive ventilation when necessary. Education and training in NIV techniques and troubleshooting are paramount to maximize therapeutic efficacy and minimize complications.

In parallel, these insights invite a reexamination of adjunct therapies aimed at mitigating BPD risk, including pharmacological agents like corticosteroids, antioxidant therapies, and surfactant administration methods complemented by NIV. Investigations into genetic and epigenetic predispositions to BPD may further reveal why some infants fail to benefit from non-invasive strategies, enabling precision medicine approaches in neonatal care.

The study by Goffinon et al. also calls attention to the evolving epidemiology of prematurity and lung disease. Advances in obstetric care have increased the survival of extremely low gestational age newborns, paradoxically raising the population at risk for BPD. The challenge lies in refining respiratory support to support lung growth without inflicting additional injury — a delicate balance that demands ongoing innovation and rigorous clinical scrutiny.

Collectively, these revelations serve as a stark reminder that technological advancements in neonatal medicine do not automatically translate to improved outcomes without continuous evaluation and adaptation. The relationship between NIV and BPD exemplifies the complexities inherent in critical care interventions where multiple interacting factors influence disease progression and recovery. As such, the neonatal community must maintain a vigilant, evidence-driven approach to respiratory management, integrating emerging data with clinical acumen to optimize care for the most fragile patients.

In closing, while non-invasive ventilation represents a paradigm shift with immense potential, the paradoxical rise in bronchopulmonary dysplasia documented by Goffinon et al. underscores the necessity for continual reassessment of practice standards. The pursuit of safer, more effective respiratory support must persist with rigor and humility, embracing multidisciplinary collaboration, innovation, and patient-centered research. The fragile lungs of premature infants deserve nothing less than our most dedicated scientific and clinical efforts.

Subject of Research: The impact of non-invasive ventilation on the incidence and outcomes of bronchopulmonary dysplasia in preterm infants.

Article Title: Rising rates of non-invasive ventilation and bronchopulmonary dysplasia: A propensity score-matched analysis.

Article References:
Goffinon, E., Badr, D.A., Lefèvre, N. et al. Rising rates of non-invasive ventilation and bronchopulmonary dysplasia: A propensity score-matched analysis. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02494-9

Image Credits: AI Generated

DOI: 24 November 2025